Day-one subcutaneous Leqembi means patients newly diagnosed with mild cognitive impairment or mild Alzheimer's dementia can now start treatment with the weekly autoinjector, instead of beginning on intravenous infusions first. The FDA approved Leqembi Iqlik (subcutaneous lecanemab-irmb) on July 13, 2026 as a once-weekly autoinjector usable as the initiation dose for early Alzheimer's disease, extending beyond its earlier maintenance-only role, according to Biogen's July 13, 2026 press release.
Eisai and Biogen planned the U.S. launch of this initiation-dose version for late August 2026, following the approval, according to Practical Neurology. This checklist covers what a patient or caregiver needs in place before that first injection.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Changed, and Who Can Start on It Now
- Pre-Treatment Testing to Schedule Before Day One
- The Monitoring Schedule During the First 14 Weeks
- What to Expect From the Injection Itself
- Cost and What It Means for Combination Treatment
- Frequently Asked Questions
What Changed, and Who Can Start on It Now
The FDA first cleared the subcutaneous autoinjector in August 2025, but only for maintenance use — patients had to complete at least 18 months of IV Leqembi first, and that version launched in the U.S. on October 6, 2025, according to Biogen and Eisai's 2025 launch materials.
The July 2026 approval removes that requirement for new patients: someone diagnosed today can go straight to the weekly injection without ever starting on an IV line. Leqembi (lecanemab) remains indicated specifically for the mild cognitive impairment or mild dementia stage of Alzheimer's disease, the population studied in its pivotal trials — it is not approved for moderate or later-stage dementia, per the FDA-approved prescribing information. A diagnosis confirming that stage, rather than more advanced dementia, is the first gate a patient needs to clear before this option applies.
Pre-Treatment Testing to Schedule Before Day One
Two tests are standard before any lecanemab treatment starts, IV or subcutaneous. ARIA risk — amyloid-related imaging abnormalities, a side effect involving brain swelling or small bleeds — is substantially higher in patients who carry two copies of the APOE ε4 gene, and higher still in anyone with pre-existing microhemorrhages or superficial siderosis on brain imaging, according to the FDA prescribing information. That makes APOE genotyping and a baseline MRI standard pre-treatment steps.
- Ask the prescribing neurologist to order APOE ε4 genotyping before the first dose, since the result shapes the monitoring plan.
- Schedule a baseline brain MRI; this is the scan clinicians compare against during the higher-risk early months.
- Confirm the mild cognitive impairment or mild dementia diagnosis is documented, since that stage is what the approval covers.
- Bring a list of current medications, especially any blood thinners, since these affect ARIA risk discussions.
The Monitoring Schedule During the First 14 Weeks
The FDA label requires enhanced clinical vigilance for ARIA during roughly the first 14 weeks of treatment, with periodic MRI monitoring, regardless of whether the drug is given by IV or by the subcutaneous autoinjector, per the FDA prescribing information. Patients and caregivers should expect this window to involve more frequent imaging appointments than the weekly injection schedule alone would suggest, since the injection itself takes about 15 seconds and delivers a 360 mg dose at home, according to Eisai and Biogen's launch materials.
Caregivers are often the ones who notice early ARIA symptoms — headache, confusion, vision changes, dizziness, or nausea — since the person being treated may not recognize a subtle change in themselves. Report any new neurological symptom to the prescribing clinic right away during this period rather than waiting for the next scheduled scan.
What to Expect From the Injection Itself
The autoinjector delivers 360 mg once weekly in about 15 seconds, and it is designed so patients can give themselves the injection at home instead of making biweekly trips to an infusion center, according to Eisai and Biogen's launch materials. A clinician or nurse typically walks a patient and caregiver through the first injection or first few before the patient administers it solo.
The subcutaneous form carries its own distinct risk, separate from ARIA: localized injection-site reactions, including redness, swelling, pain, bruising, and hematoma at the injection site. These reactions are generally mild to moderate, but The Medical Letter reports they have caused some patients to stop treatment. Rotating injection sites and reviewing technique with a nurse during early visits can reduce the chance of a reaction severe enough to disrupt the schedule.
Cost and What It Means for Combination Treatment
The subcutaneous maintenance autoinjector carried a wholesale acquisition cost of about $375 per weekly injection when it launched in October 2025, which comes to roughly $19,500 a year — comparable to the IV formulation's annual cost, according to Precision Medicine Online. Patients should confirm with their insurer how this initiation-dose approval affects coverage, since plans may have built prior authorization criteria around the older IV-first pathway.
The Alzheimer's Drug Discovery Foundation stated that the 2026 approval of a subcutaneous starting dose moves Leqembi toward easier combination with other emerging Alzheimer's therapies, because it reduces the infusion-center burden on patients and caregivers, according to the ADDF's July 2026 statement. For a patient weighing whether a future second drug might be layered onto Leqembi, that lower logistical burden is a factor worth raising directly with the prescribing neurologist now.
Frequently Asked Questions
Does starting on the subcutaneous version skip the IV infusions entirely?
Yes — the July 2026 approval lets new patients begin treatment with the weekly autoinjector, with no prior IV infusions required, unlike the October 2025 version that was restricted to patients who had already completed 18 months of IV treatment.
Is the monitoring schedule different for subcutaneous versus IV Leqembi?
No — the FDA's requirement for enhanced ARIA vigilance and periodic MRI monitoring during roughly the first 14 weeks applies the same way regardless of which formulation a patient uses.
Can someone with moderate Alzheimer's dementia start this version?
No — the approval covers only the mild cognitive impairment and mild dementia stages studied in Leqembi's pivotal trials.
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: Access, Cost, and Follow-Up Questions for People With Mild Cognitive Impairment
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Access, Cost, and Follow-Up Questions for People With Mild Cognitive Impairment
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: Access, Cost, and Follow-Up Questions for People With Mild Cognitive Impairment
